FLAVIA BALBO PIAZZON

(Fonte: Lattes)
Índice h a partir de 2011
4
Lattes
Projetos de Pesquisa
Unidades Organizacionais
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Colaboração internacional: Alemanha ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 48 Citação(ões) na Scopus
    Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to alpha-aminoadipic semialdehyde dehydrogenase deficiency
    (2021) II, Curtis R. Coughlin; TSENG, Laura A.; ABDENUR, Jose E.; ASHMORE, Catherine; BOEMER, Francois; BOK, Levinus A.; BOYER, Monica; BUHAS, Daniela; CLAYTON, Peter T.; DAS, Anibh; DEKKER, Hanka; EVANGELIOU, Athanasios; FEILLET, Francois; FOOTITT, Emma J.; GOSPE JR., Sidney M.; HARTMANN, Hans; KARA, Majdi; KRISTENSEN, Erle; LEE, Joy; LILJE, Rina; LONGO, Nicola; LUNSING, Roelineke J.; MILLS, Philippa; PAPADOPOULOU, Maria T.; PEARL, Phillip L.; PIAZZON, Flavia; PLECKO, Barbara; SAINI, Arushi G.; SANTRA, Saikat; SJARIF, Damayanti R.; STOCKLER-IPSIROGLU, Sylvia; STRIANO, Pasquale; HOVE, Johan L. K. Van; VERHOEVEN-DUIF, Nanda M.; WIJBURG, Frits A.; ZUBERI, Sameer M.; KARNEBEEK, Clara D. M. van
    Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an autosomal recessive condition due to a deficiency of alpha-aminoadipic semialdehyde dehydrogenase, which is a key enzyme in lysine oxidation. PDE-ALDH7A1 is a developmental and epileptic encephalopathy that was historically and empirically treated with pharmacologic doses of pyridoxine. Despite adequate seizure control, most patients with PDE-ALDH7A1 were reported to have developmental delay and intellectual disability. To improve outcome, a lysine-restricted diet and competitive inhibition of lysine transport through the use of pharmacologic doses of arginine have been recommended as an adjunct therapy. These lysine-reduction therapies have resulted in improved biochemical parameters and cognitive development in many but not all patients. The goal of these consensus guidelines is to re-evaluate and update the two previously published recommendations for diagnosis, treatment, and follow-up of patients with PDE-ALDH7A1. Members of the International PDE Consortium initiated evidence and consensus-based process to review previous recommendations, new research findings, and relevant clinical aspects of PDE-ALDH7A1. The guideline development group included pediatric neurologists, biochemical geneticists, clinical geneticists, laboratory scientists, and metabolic dieticians representing 29 institutions from 16 countries. Consensus guidelines for the diagnosis and management of patients with PDE-ALDH7A1 are provided.